Impact of body mass index on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone

Br J Haematol. 2014 Dec;167(5):699-702. doi: 10.1111/bjh.13026. Epub 2014 Jul 15.
No abstract available

Keywords: diffuse large B-cell lymphoma; empiric dose-reduction; non-Hodgkin lymphoma; obesity; treatment-related toxicity.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Body Mass Index*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Febrile Neutropenia* / chemically induced
  • Febrile Neutropenia* / drug therapy
  • Febrile Neutropenia* / mortality
  • Female
  • Humans
  • Incidence
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / mortality
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Retrospective Studies
  • Rituximab
  • United States / epidemiology
  • Veterans*
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone